US EditionESCMID Global 2025: Initial ABI-5366 data supports monthly dosing for genital herpes
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
ESCMID Global 2025: Initial ABI-5366 data supports monthly dosing for genital herpes
At ESCMID 2025, early data suggest that Assembly Biosciences’ ABI-5366 could redefine the treatment landscape for recurrent genital herpes (RGH).The post ESCMID Global 2025: Initial ABI-5366 data supports monthly dosing for genital herpes appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage